Home » Stocks » CDTX

Cidara Therapeutics, Inc. (CDTX)

Stock Price: $2.31 USD 0.04 (1.76%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $2.21 -0.10 (-4.33%) Nov 24, 6:22 PM

Stock Price Chart

Key Info

Market Cap 101.50M
Revenue (ttm) 10.15M
Net Income (ttm) -67.26M
Shares Out 43.94M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $2.31
Previous Close $2.27
Change ($) 0.04
Change (%) 1.76%
Day's Open 2.27
Day's Range 2.21 - 2.35
Day's Volume 140,178
52-Week Range 1.30 - 4.45

More Stats

Market Cap 101.50M
Enterprise Value 57.11M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 43.94M
Float 31.26M
EPS (basic) -1.65
EPS (diluted) -1.65
FCF / Share -1.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.92M
Short Ratio 19.30
Short % of Float 6.15%
Beta 1.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.00
PB Ratio 3.70
Revenue 10.15M
Operating Income -64.38M
Net Income -67.26M
Free Cash Flow -58.67M
Net Cash 44.38M
Net Cash / Share 1.01
Gross Margin -251.02%
Operating Margin -634.11%
Profit Margin -662.50%
FCF Margin -577.82%
ROA -55.36%
ROE -164.30%
ROIC 582.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(194.37% upside)
Current: $2.31
Target: 6.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit20.92------
Operating Income-41.72-63.29-55.72-48.44-32.31-11.62-1.08
Net Income-41.09-59.02-55.73-48.17-32.19-11.89-1.34
Shares Outstanding29.0925.1417.5014.499.920.820.32
Earnings Per Share-1.41-2.76-3.18-3.32-3.25-14.51-4.15
Operating Cash Flow-28.53-56.71-49.91-39.77-25.96-7.71-1.05
Capital Expenditures-0.04-0.18-0.31-0.40-1.17-0.99-
Free Cash Flow-28.57-56.88-50.22-40.17-27.13-8.70-1.05
Cash & Equivalents60.2774.5675.3110510822.800.19
Total Debt11.739.939.879.79--1.48
Net Cash / Debt48.5464.6365.4494.8310822.80-1.30
Book Value37.8459.1459.7488.18104-11.45-1.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cidara Therapeutics, Inc.
Country United States
Employees 68
CEO Jeffrey L. Stein

Stock Information

Ticker Symbol CDTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CDTX
IPO Date April 15, 2015


Cidara Therapeutics, a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.